Epicrispr Biotechnologies vs Transcripta Bio

Epicrispr Biotechnologies vs Transcripta Bio, compared side by side on 18 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Epicrispr Biotechnologies is on 62/100 and Transcripta Bio on 54/100.

Epicrispr Biotechnologies logo
Epicrispr BiotechnologiesEpicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
Try Epicrispr Biotechnologies
Transcripta Bio logo
Transcripta BioAI-powered drug discovery company focused on neurological and neuromuscular diseases, leveraging transcriptomics to accelerate therapeutic development.
Try Transcripta Bio

Where each one leads

Epicrispr Biotechnologies

  • our overall score: 62/100 against 54/100
  • funding raised: $90.0M against $24.0M

Transcripta Bio

  • agent readiness: 49/100 against 39/100

At a glance

MeasureEpicrispr BiotechnologiesTranscripta Bio
What it isEpicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).AI-powered drug discovery company focused on neurological and neuromuscular diseases, leveraging transcriptomics to accelerate therapeutic development.
CategoryBiotechnology, Therapeutics, Rare Diseases, EpigeneticsBiotechnology, Artificial Intelligence, Drug Discovery, Neurology
Sells toBusiness modelB2BB2B
OfferingPlatformPlatform
Founded20202023
HeadquartersSouth San Francisco, United StatesPalo Alto, United States
StatusActiveActive

Size, funding and growth

MeasureEpicrispr BiotechnologiesTranscripta Bio
Employees51Not published
Total funding$90.0M$24.0M
Latest roundSeries CSeries A
LinkedIn followers7,025Not published

StartupHub scores

Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.

MeasureEpicrispr BiotechnologiesTranscripta Bio
StartupHub scoreOur 0-100 rating62/10054/100
Traction57/10037/100
Team40/10050/100
Search visibility20/10017/100
Quality78/10068/100
Agent readinessHow well an AI agent can read and act on the siteF (39/100)D (49/100)
Domain ratingLink authority, 0-10040/10037/100

Technology

Detected on each public site, so it reflects the marketing stack as well as the product.

MeasureEpicrispr BiotechnologiesTranscripta Bio
CDNCloudflareNot detected
CMSWordPressNot detected
FrameworksJquery, Tailwind CSS, BootstrapNext.js, Tailwind CSS
AnalyticsGoogle Analytics 4Google Analytics 4

What users say

MeasureEpicrispr BiotechnologiesTranscripta Bio
Reddit sentimentThreads we trackNot published1 positive, 0 negative across 1 thread
Transcripta Bio
Transcripta Bio Wins the Genomics Category 🧬💻. Transcripta Bio took home the trophy for Genomics, and for good reason. They are bridging the gap between massive transcriptomic data and actual drug candidates.
r/AIDiscoveryAward

Epicrispr Biotechnologies vs Transcripta Bio: common questions

Which is better, Epicrispr Biotechnologies or Transcripta Bio?

On our 0-100 score Epicrispr Biotechnologies rates higher (62/100 against 54/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 18 data points above: read the rows that match what you are buying for.

How do Epicrispr Biotechnologies and Transcripta Bio compare on the numbers?

Epicrispr Biotechnologies leads on our overall score (62/100 against 54/100), funding raised ($90.0M against $24.0M). Transcripta Bio leads on agent readiness (49/100 against 39/100).

What do real users say about Epicrispr Biotechnologies and Transcripta Bio?

Transcripta Bio: 1 positive and 0 negative mentions across 1 Reddit threads we track, mostly in r/AIDiscoveryAward.

Read the full Epicrispr Biotechnologies review and pricing or the Transcripta Bio review and pricing. You can also browse other Epicrispr Biotechnologies alternatives we track.